Cholesterol-lowering strategies reduce vascular LRP1 overexpression induced by hypercholesterolaemia

European Journal of Clinical Investigation

Volumn 41, Issue 10, 2011, Pages 1087-1097

  Llorente Cortes, Vicenta ^a   Casani, Laura ^a,b   Cal, Roi ^a   Llenas, Albert ^a   Juan Babot, Oriol ^a   Camino López, Sandra ^a   Sendra, Judith ^a   Badimon Maestro, Lina ^a,b  

^a CSIC   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Atherosclerosis; HMG CoA reductase inhibitors; Hypercholesterolemia; Lipid deposition; Low density lipoprotein receptor related protein (LRP1)

Indexed keywords

CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; BLOOD VESSEL WALL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; EXPERIMENTAL RABBIT; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SMOOTH MUSCLE FIBER;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; ENDOTHELIUM, VASCULAR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MALE; RABBITS; REAL-TIME POLYMERASE CHAIN REACTION; SIMVASTATIN;

EID: 80052622164     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02513.x     Document Type: Article

References (51)

1. Grodos D, Tonglet R. Scandinavian simvastatin study (4S). Lancet 1994;344:8939-40.
2. Simes RJ. Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. Am J Cardiol 1995;76:122C-6C.
3. Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol 1995;76:113C-7C.
4. Brown MS, Herz J, Goldstein JL. LDL-receptor structure. Calcium cages, acid baths and recycling receptors. Nature 1997;388:629-30.
5. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:III39-43.
6. Paoletti R, Bellosta S, Bernini F. Pharmacological control of phagocyte function: inhibition of cholesterol accumulation. Ann N Y Acad Sci 1997;832:322-9.
7. Hofnagel O, Luechtenborg B, Weissen-Plenz G, Robenek H. Statins and foam cell formation impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochim Biophys Acta 2007;1771:1117-24.
8. Hiltunen TP, Luoma JS, Nikkari T, Ylä-Herttuala S. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation 1998;97:1079-86.
9. Moestrup SK, Gliemann J, Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res 1992;269:375-82.
10. Luoma J, Hiltunen T, Särkioja T, Moestrup SK, Gliemann J, Kodama T et al. Expression of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions. J Clin Invest 1994;93:2014-21.
11. Llorente-Cortés V, Otero-Viñas M, Berrozpe M, Badimon L. Intracellular lipid accumulation, low-density lipoprotein receptor-related protein expression, and cell survival in vascular smooth muscle cells derived from normal and atherosclerotic human coronaries. Eur J Clin Invest 2004;34:182-90.
12. Llorente-Cortés V, Otero-Viñas M, Hurt-Camejo E, Martínez-González J, Badimon L. Human coronary smooth muscle cells internalize versican-modified LDL through LDL receptor-related protein and LDL receptors. Arterioscler Thromb Vasc Biol 2002;22:387-93.
13. Llorente-Cortés V, Royo T, Juan-Babot O, Badimon L. Adipocyte differentiation-related protein is induced by LRP1-mediated aggregated LDL internalization in human vascular smooth muscle cells and macrophages. J Lipid Res 2007;48:2133-40.
14. Llorente-Cortés V, Otero-Viñas M, Camino-López S, Costales P, Badimon L. Cholesteryl esters of aggregated LDL are internalized by selective uptake in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2006;26:117-23.
15. Llorente-Cortés V, Badimon L. LDL receptor-related protein and the vascular wall: implications for atherothrombosis. Arterioscler Thromb Vasc Biol 2005;25:497-504.
16. Gaultier A, Salicioni AM, Arandjelovic S, Gonias SL. Regulation of the composition of the extracellular matrix by low density lipoprotein receptor-related protein-1: activities based on regulation of mRNA expression. J Biol Chem 2006;281:7332-40.
17. Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 2006;281:2120-7.
18. Padmasekar M, Nandigama R, Wartenberg M, Schlüter KD, Sauer H. The acute phase protein alpha2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1, 2 and PI3-kinase/Akt pathways. Cardiovasc Res 2007;75:118-28.
19. Wang S, Herndon ME, Ranganathan S, Godyna S, Lawler J, Argraves WS et al. Internalization but not binding of thrombospondin-1 to low density lipoprotein receptor-related protein-1 requires heparan sulfate proteoglycans. J Cell Biochem 2004;91:766-76.
20. Espirito Santo SM, Pires NM, Boesten LS, Gerritsen G, Bovenschen N, van Dijk KW et al. Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol. Blood 2004;103:3777-82.
21. Hu L, Boesten LS, May P, Herz J, Bovenschen N, Huisman MV et al. Macrophage low-density lipoprotein receptor-related protein deficiency enhances atherosclerosis in ApoE/LDLR double knockout mice. Arterioscler Thromb Vasc Biol 2006;26:2710-5.
22. Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J. LRP: role in vascular wall integrity and protection from atherosclerosis. Science 2003;300:329-32.
23. Llorente-Cortés V, Otero-Viñas M, Sánchez S, Rodríguez C, Badimon L. Low density lipoprotein up-regulates low density lipoprotein receptor-related protein expression in vascular smooth muscle cells. Possible involvement of sterol regulatory element binding protein-2-dependent mechanism. Circulation 2002;106:31104-10.
24. Llorente-Cortés V, Costales P, Bernués J, Camino-Lopez S, Badimon L. Sterol regulatory element-binding protein-2 negatively regulates low density lipoprotein receptor-related protein transcription. J Mol Biol 2006;359:950-60.
25. Costales P, Aledo R, Vérnia S, Das A, Shah VH, Casado M et al. Selective role of sterol regulatory element binding protein isoforms in aggregated LDL-induced vascular low density lipoprotein receptor-related protein-1 expression. Atherosclerosis 2010;213:458-68.
26. Pocathikorn A, Taylor RR, Mamotte CDS. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells. Clin Exp Pharmacol Physiol 2010;37:471-6.
27. Kim S, Kim CH, Vaziri ND. Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy. Am J Physiol Endocrinol Metab 2005;288:E813-7.
28. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002;106:2884-7.
29. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005;46:106-12.
30. Verschuren L, Kleemann R, Offerman EH, Szalai AJ, Emeis SJ, Princen HM et al. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 2005;25:161-7.
31. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003;108:1368-74.
32. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 2006;281:15099-109.
33. Meyers CD, Tannock LR, Wight TN, Chait A. Statin-exposed vascular smooth muscle cells secrete proteoglycans with decreased binding affinity for LDL. J Lipid Res 2003;44:2152-60.
34. Mandosi E, Fallarino M, Gatti A, Carnovale A, Rossetti M, Lococo E et al. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes. J Atheroscler Thromb 2010;17:539-45.
35. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2010; [Epub ahead of print].
36. Rodrigues Díez R, Rodrigues-Díez R, Lavoz C, Rayego-Mateos S, Civantos E, Rodríguez-Vita J et al. Statins inhibit angiotensin II/Smad Pathway and related vascular fibrosis, by a TGF-β-independent process. PLoS ONE 2010;5:e14145.
37. Araújo FA, Rocha MA, Mendes JB, Andrade SP. Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1. Biomed Pharmacother 2010;64:29-34.
38. Ceschin DG, Sánchez MC, Chiabrando GA. Insulin induces the low density lipoprotein receptor-related protein 1 (LRP1) degradation by the proteasomal system in J774 macrophage-derived cells. J Cell Biochem 2009;106:372-80.
39. Laatsch A, Merkel M, Talmud PJ, Grewal T, Beisiegel U, Heeren J. Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. Atherosclerosis 2009;204:105-11.
40. Sendra J, Llorente-Cortés V, Costales P, Huesca-Gómez C, Badimon L. Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. Cardiovasc Res 2008;78:581-9.
41. Eslami P, Johnson MF, Terzakaryan E, Chew C, Harris-White ME. TGF beta2-induced changes in LRP-1/T beta R-V and the impact on lysosomal A beta uptake and neurotoxicity. Brain Res 2008;1241:176-87.
42. Hofmann SM, Zhou L, Perez-Tilve D, Greer T, Grant E, Wancata L et al. Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice. J Clin Invest 2007;117:3271-82.
43. Tamaki C, Ohtsuki S, Terasaki T. Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein (LRP1) to the plasma membrane in hepatocytes. Mol Pharmacol 2007;72:850-5.
44. Zhang H, Lee JM, Wang Y, Dong L, Ko KW, Pelletier L et al. Mutational analysis of the FXNPXY motif within LDL receptor-related protein 1 (LRP1) reveals the functional importance of the tyrosine residues in cell growth regulation and signal transduction. Biochem J 2008;409:53-64.
45. Risé P, Ghezzi S, Carissimi R, Mastromauro F, Petroni A, Galli C. Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur J Pharmacol 2007;571:97-105.
46. Hsu MH, Savas U, Griffin KJ, Johnson EF. Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin. J Biol Chem 2007;282:5225-36.
47. Wojcik C, Bury M, Stoklosa T, Giermasz A, Feleszko W, Mlynarczuk I et al. Lovastatin and simvastatin are modulators of the proteasome. Int J Biochem Cell Biol 2000;32:957-65.
48. Murray SS, Tu KN, Young KL, Murray EJ. The effects of lovastatin on proteasome activities in highly purified rabbit 20s proteasome preparations and mouse MC3T3-E1 osteoblastic cells. Metabolism 2002;51:1153-60.
49. Melman L, Geuze HJ, Li Y, McCormick LM, Van Kerkhof P, Strous GJ et al. Proteasome regulates the delivery of LDL receptor-related protein into the degradation pathway. Mol Biol Cell 2002;13:3325-35.
50. Ye P, Yu D, Song L, Deng X, Zhao Y. Inhibitory effect of fluvastatin on aortic intimal thickening in normocholesterolemic rabbits. Chin Med Sci J 2000;15:140-4.
51. Yamakawa T, Tanaka S, Kamei J, Kadonosono K, Okuda K. Pitavastatin inhibits vascular smooth muscle cell proliferation by inactivating extracellular signal-regulated kinases 1/2. J Atheroscler Thromb 2003;10:37-42.